# TEIPP Immunotherapy in Patients With NSCLC

> **NCT05898763** · PHASE1,PHASE2 · COMPLETED · sponsor: **Erasmus Medical Center** · enrollment: 26 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** TEIPP24 (LRPAP7-30V-SLP vaccine in Montanide ISA-51)

## Key facts

- **NCT ID:** NCT05898763
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-29
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05898763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05898763, "TEIPP Immunotherapy in Patients With NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05898763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*